Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.

Autoimmune Encephalitis Clinical Trial

— SALTEA GABAbr  

Official title:

Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05741619
• Other study ID #: 897
• Status: Completed
• Start date: January 1, 2022
• Est. completion date: September 1, 2022

Study information

• Verified date: February 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC). While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative. In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 70
• Est. completion date: September 1, 2022
• Est. primary completion date: June 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• encephalitis tested positive to GABAbr-antibodies after the examination of CSF samples tested for autoimmune encephalitis at the French Paraneoplastic Neurological Syndrome Reference Center from January 2011 to January 2022.

Exclusion Criteria:

• tested positive to another onconeural antibody.

Related Conditions & MeSH terms

• Autoimmune Encephalitis
• Encephalitis

Intervention

Other:
• Long-term outcome
Autonomy, physical examination, behavioural disorders

Locations

Country	Name	City	State
France	Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites autoimmunes	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Modified-Rankin scale (mRS)	Modified-Rankin scale (mRS) ranked from 0 (full autonomy) to 6 (death)	At 60 month (after the beginning of the disease)